title: Plerixafor prescription modalities in autologous haematopoietic stem cell mobilization in Belgium.
abstract: OBJECTIVE
  The efficacy and safety of plerixafor, an antagonist of the CXCR4 receptor, in combination with G-CSF has been demonstrated in patients suffering from Iymphoma and multiple myeloma (MM) eligible for autologous haematopoietic stem cell collection. However, different reimbursement criteria have been applied in different countries to select patients eligible for treatment with plerixafor. The objective of this observational study was to describe the plerixafor prescription modalities in daily practice in Belgium.
  
  
  METHODS
  This open-label, prospective, observational study was conducted in 11 Belgian centres in 114 patients with lymphoma (Hodgkin's and non-Hodgkin's lymphoma) or MM who were treated with plerixafor according to the SmPC between April 2011 and October 2012. Patients included in another clinical trial with plerixafor were excluded from the study.
  
  
  RESULTS
  The use of plerixafor in patients with MM or lymphoma was effective, with a success rate (defined as a total yield >2×10(6) CD34+ cells/kg) of 77%, and well tolerated (one SAE reported). Optimal collection (defined as a total yield >4×10(6) CD34+ cells/kg) was obtained for 43% of the study population (31% in lymphoma patients, compared to 61% in patients with MM). The use of plerixafor was in line with the SmPC and the Belgian reimbursement criteria for all patients.
  
  
  CONCLUSIONS
  This study is showing that the use of plerixafor according to Belgian reimbursement criteria results in similar efficacy and safety as in other centres and countries worldwide.
authors.forename: D
authors.initials: D
authors.lastname: Selleslag
authors.forename: C
authors.initials: C
authors.lastname: Lambert
authors.forename: P
authors.initials: P
authors.lastname: Zachee
authors.forename: P
authors.initials: P
authors.lastname: Huyngh
authors.forename: A
authors.initials: A
authors.lastname: Van de Velde
authors.forename: L
authors.initials: L
authors.lastname: Noens
authors.forename: L
authors.initials: L
authors.lastname: Baily
authors.forename: M
authors.initials: M
authors.lastname: André
authors.forename: E
authors.initials: E
authors.lastname: Willems
authors.forename: D
authors.initials: D
authors.lastname: Dierickx
mesh_terms: D000328:Adult; D000368:Aged; D001530:Belgium; D001596:Benzylamines; D000080027:Cyclams; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006571:Heterocyclic Compounds / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D010818:Practice Patterns, Physicians'; D011446:Prospective Studies; D014182:Transplantation, Autologous
chemical_list: D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; C088327:plerixafor
keywords: Hodgkin’s lymphoma; Multiple myeloma,; Non-Hodgkin’s lymphoma,; Plerixafor,; Poor mobilizers,